Immuron Ltd News Today

The ASX200 made some solid progress today, notching a 20.50-point or 0.26% gain to 7,844.70 points. The bourse hit a peak of 7,896 points at the end of...

This article was automatically generated by Dow Jones Newswires using technology from Automated Insights. International stocks trading in New York closed lower on Monday, as the S&P/BNY Mellon... -March 11, 2024 at 05:06 pm EDT - MarketScreener

The US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic...

It’s been a difficult quarter for the biotech sector, with economies struggling to recover from high inflation making for a small appetite for risk. The ASX...

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has received a bull case valuation of A$0.35 and a base case valuation of A$0.25 from Pitt Street Research in a report....

Globally integrated biopharmaceutical company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has initiated the second cohort of a clinical trial aimed at assessing the...

ASX Futures are pointing to a strong slide in early trading today, with the ASX likely to fall 83 points or 1.2%, following tumbling US and European markets...

Australia’s benchmark index ended the session down 1.5% as local investors followed Wall Streets lead overnight on worries about rising Middle East...

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore will be presenting at the 16th annual LD Micro Main Event on Wednesday, October 4th at 11:00 PT at...

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its...